Global Anti-VEGF Therapy for Cancer Market Research Report 2026

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 VEGF Inhibitors
1.2.3 VEGFR Inhibitors
1.3 Market by Application
1.3.1 Global Anti-VEGF Therapy for Cancer Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Colorectal Cancer
1.3.3 Non-small Cell Lung Cancer
1.3.4 Renal Cell Carcinoma
1.3.5 Cervical Cancer
1.3.6 Medullary Thyroid Cancer
1.3.7 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-VEGF Therapy for Cancer Market Perspective (2021–2032)
2.2 Global Anti-VEGF Therapy for Cancer Growth Trends by Region
2.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Anti-VEGF Therapy for Cancer Historic Market Size by Region (2021–2026)
2.2.3 Anti-VEGF Therapy for Cancer Forecasted Market Size by Region (2027–2032)
2.3 Anti-VEGF Therapy for Cancer Market Dynamics
2.3.1 Anti-VEGF Therapy for Cancer Industry Trends
2.3.2 Anti-VEGF Therapy for Cancer Market Drivers
2.3.3 Anti-VEGF Therapy for Cancer Market Challenges
2.3.4 Anti-VEGF Therapy for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-VEGF Therapy for Cancer Players by Revenue
3.1.1 Global Top Anti-VEGF Therapy for Cancer Players by Revenue (2021–2026)
3.1.2 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Players (2021–2026)
3.2 Global Top Anti-VEGF Therapy for Cancer Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Anti-VEGF Therapy for Cancer Revenue
3.4 Global Anti-VEGF Therapy for Cancer Market Concentration Ratio
3.4.1 Global Anti-VEGF Therapy for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-VEGF Therapy for Cancer Revenue in 2025
3.5 Global Key Players of Anti-VEGF Therapy for Cancer Head Offices and Areas Served
3.6 Global Key Players of Anti-VEGF Therapy for Cancer, Products and Applications
3.7 Global Key Players of Anti-VEGF Therapy for Cancer, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Anti-VEGF Therapy for Cancer Breakdown Data by Type
4.1 Global Anti-VEGF Therapy for Cancer Historic Market Size by Type (2021–2026)
4.2 Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Type (2027–2032)
5 Anti-VEGF Therapy for Cancer Breakdown Data by Application
5.1 Global Anti-VEGF Therapy for Cancer Historic Market Size by Application (2021–2026)
5.2 Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Anti-VEGF Therapy for Cancer Market Size (2021–2032)
6.2 North America Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Anti-VEGF Therapy for Cancer Market Size by Country (2021–2026)
6.4 North America Anti-VEGF Therapy for Cancer Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-VEGF Therapy for Cancer Market Size (2021–2032)
7.2 Europe Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021–2026)
7.4 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size (2021–2032)
8.2 Asia-Pacific Anti-VEGF Therapy for Cancer Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (2021–2026)
8.4 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Anti-VEGF Therapy for Cancer Market Size (2021–2032)
9.2 Latin America Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Anti-VEGF Therapy for Cancer Market Size by Country (2021–2026)
9.4 Latin America Anti-VEGF Therapy for Cancer Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size (2021–2032)
10.2 Middle East & Africa Anti-VEGF Therapy for Cancer Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2021–2026)
10.4 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Anti-VEGF Therapy for Cancer Introduction
11.1.4 Sanofi Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.1.5 Sanofi Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Anti-VEGF Therapy for Cancer Introduction
11.2.4 Eli Lilly Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.2.5 Eli Lilly Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Anti-VEGF Therapy for Cancer Introduction
11.3.4 Roche Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.3.5 Roche Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Anti-VEGF Therapy for Cancer Introduction
11.4.4 Bayer Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.4.5 Bayer Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Anti-VEGF Therapy for Cancer Introduction
11.5.4 Pfizer Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.5.5 Pfizer Recent Development
11.6 Jiangsu Hengrui Pharmaceuticals
11.6.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.6.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Introduction
11.6.4 Jiangsu Hengrui Pharmaceuticals Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.6.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.7 Chia Tai Tianqing
11.7.1 Chia Tai Tianqing Company Details
11.7.2 Chia Tai Tianqing Business Overview
11.7.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Introduction
11.7.4 Chia Tai Tianqing Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.7.5 Chia Tai Tianqing Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Anti-VEGF Therapy for Cancer Introduction
11.8.4 Novartis Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.8.5 Novartis Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Details
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Anti-VEGF Therapy for Cancer Introduction
11.9.4 AstraZeneca Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.9.5 AstraZeneca Recent Development
11.10 Exelixis
11.10.1 Exelixis Company Details
11.10.2 Exelixis Business Overview
11.10.3 Exelixis Anti-VEGF Therapy for Cancer Introduction
11.10.4 Exelixis Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.10.5 Exelixis Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Details
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Introduction
11.11.4 Boehringer Ingelheim Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Eisai
11.12.1 Eisai Company Details
11.12.2 Eisai Business Overview
11.12.3 Eisai Anti-VEGF Therapy for Cancer Introduction
11.12.4 Eisai Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.12.5 Eisai Recent Development
11.13 Janssen Biotech
11.13.1 Janssen Biotech Company Details
11.13.2 Janssen Biotech Business Overview
11.13.3 Janssen Biotech Anti-VEGF Therapy for Cancer Introduction
11.13.4 Janssen Biotech Revenue in Anti-VEGF Therapy for Cancer Business (2021–2026)
11.13.5 Janssen Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of VEGF Inhibitors
Table 3. Key Players of VEGFR Inhibitors
Table 4. Global Anti-VEGF Therapy for Cancer Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Anti-VEGF Therapy for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Anti-VEGF Therapy for Cancer Market Size by Region (US$ Million), 2021–2026
Table 7. Global Anti-VEGF Therapy for Cancer Market Share by Region (2021–2026)
Table 8. Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Anti-VEGF Therapy for Cancer Market Share by Region (2027–2032)
Table 10. Anti-VEGF Therapy for Cancer Market Trends
Table 11. Anti-VEGF Therapy for Cancer Market Drivers
Table 12. Anti-VEGF Therapy for Cancer Market Challenges
Table 13. Anti-VEGF Therapy for Cancer Market Restraints
Table 14. Global Anti-VEGF Therapy for Cancer Revenue by Players (US$ Million), 2021–2026
Table 15. Global Anti-VEGF Therapy for Cancer Market Share by Players (2021–2026)
Table 16. Global Top Anti-VEGF Therapy for Cancer Players by Tier (Tier 1, Tier 2, and Tier 3), based on Anti-VEGF Therapy for Cancer Revenue, 2025
Table 17. Ranking of Global Top Anti-VEGF Therapy for Cancer Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Anti-VEGF Therapy for Cancer Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Anti-VEGF Therapy for Cancer, Headquarters and Area Served
Table 20. Global Key Players of Anti-VEGF Therapy for Cancer, Products and Applications
Table 21. Global Key Players of Anti-VEGF Therapy for Cancer, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Anti-VEGF Therapy for Cancer Market Size by Type (US$ Million), 2021–2026
Table 24. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2021–2026)
Table 25. Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2027–2032)
Table 27. Global Anti-VEGF Therapy for Cancer Market Size by Application (US$ Million), 2021–2026
Table 28. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2021–2026)
Table 29. Global Anti-VEGF Therapy for Cancer Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2027–2032)
Table 31. North America Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2021–2026
Table 33. North America Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (US$ Million), 2027–2032
Table 46. Sanofi Company Details
Table 47. Sanofi Business Overview
Table 48. Sanofi Anti-VEGF Therapy for Cancer Product
Table 49. Sanofi Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 50. Sanofi Recent Development
Table 51. Eli Lilly Company Details
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Anti-VEGF Therapy for Cancer Product
Table 54. Eli Lilly Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 55. Eli Lilly Recent Development
Table 56. Roche Company Details
Table 57. Roche Business Overview
Table 58. Roche Anti-VEGF Therapy for Cancer Product
Table 59. Roche Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 60. Roche Recent Development
Table 61. Bayer Company Details
Table 62. Bayer Business Overview
Table 63. Bayer Anti-VEGF Therapy for Cancer Product
Table 64. Bayer Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 65. Bayer Recent Development
Table 66. Pfizer Company Details
Table 67. Pfizer Business Overview
Table 68. Pfizer Anti-VEGF Therapy for Cancer Product
Table 69. Pfizer Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 70. Pfizer Recent Development
Table 71. Jiangsu Hengrui Pharmaceuticals Company Details
Table 72. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 73. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product
Table 74. Jiangsu Hengrui Pharmaceuticals Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 75. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 76. Chia Tai Tianqing Company Details
Table 77. Chia Tai Tianqing Business Overview
Table 78. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product
Table 79. Chia Tai Tianqing Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 80. Chia Tai Tianqing Recent Development
Table 81. Novartis Company Details
Table 82. Novartis Business Overview
Table 83. Novartis Anti-VEGF Therapy for Cancer Product
Table 84. Novartis Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 85. Novartis Recent Development
Table 86. AstraZeneca Company Details
Table 87. AstraZeneca Business Overview
Table 88. AstraZeneca Anti-VEGF Therapy for Cancer Product
Table 89. AstraZeneca Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 90. AstraZeneca Recent Development
Table 91. Exelixis Company Details
Table 92. Exelixis Business Overview
Table 93. Exelixis Anti-VEGF Therapy for Cancer Product
Table 94. Exelixis Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 95. Exelixis Recent Development
Table 96. Boehringer Ingelheim Company Details
Table 97. Boehringer Ingelheim Business Overview
Table 98. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product
Table 99. Boehringer Ingelheim Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 100. Boehringer Ingelheim Recent Development
Table 101. Eisai Company Details
Table 102. Eisai Business Overview
Table 103. Eisai Anti-VEGF Therapy for Cancer Product
Table 104. Eisai Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 105. Eisai Recent Development
Table 106. Janssen Biotech Company Details
Table 107. Janssen Biotech Business Overview
Table 108. Janssen Biotech Anti-VEGF Therapy for Cancer Product
Table 109. Janssen Biotech Revenue in Anti-VEGF Therapy for Cancer Business (US$ Million), 2021–2026
Table 110. Janssen Biotech Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report


List of Figures
Figure 1. Anti-VEGF Therapy for Cancer Picture
Figure 2. Global Anti-VEGF Therapy for Cancer Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Anti-VEGF Therapy for Cancer Market Share by Type: 2025 vs 2032
Figure 4. VEGF Inhibitors Features
Figure 5. VEGFR Inhibitors Features
Figure 6. Global Anti-VEGF Therapy for Cancer Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Anti-VEGF Therapy for Cancer Market Share by Application: 2025 vs 2032
Figure 8. Colorectal Cancer Case Studies
Figure 9. Non-small Cell Lung Cancer Case Studies
Figure 10. Renal Cell Carcinoma Case Studies
Figure 11. Cervical Cancer Case Studies
Figure 12. Medullary Thyroid Cancer Case Studies
Figure 13. Other Case Studies
Figure 14. Anti-VEGF Therapy for Cancer Report Years Considered
Figure 15. Global Anti-VEGF Therapy for Cancer Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Anti-VEGF Therapy for Cancer Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Anti-VEGF Therapy for Cancer Market Share by Region: 2025 vs 2032
Figure 18. Global Anti-VEGF Therapy for Cancer Market Share by Players in 2025
Figure 19. Global Anti-VEGF Therapy for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Anti-VEGF Therapy for Cancer Revenue in 2025
Figure 21. North America Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Anti-VEGF Therapy for Cancer Market Share by Country (2021–2032)
Figure 23. United States Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Anti-VEGF Therapy for Cancer Market Share by Country (2021–2032)
Figure 27. Germany Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Anti-VEGF Therapy for Cancer Market Share by Region (2021–2032)
Figure 35. China Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Anti-VEGF Therapy for Cancer Market Share by Country (2021–2032)
Figure 43. Mexico Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Anti-VEGF Therapy for Cancer Market Share by Country (2021–2032)
Figure 47. Israel Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Anti-VEGF Therapy for Cancer Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Sanofi Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 51. Eli Lilly Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 52. Roche Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 53. Bayer Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 54. Pfizer Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 55. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 56. Chia Tai Tianqing Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 57. Novartis Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 58. AstraZeneca Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 59. Exelixis Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 60. Boehringer Ingelheim Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 61. Eisai Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 62. Janssen Biotech Revenue Growth Rate in Anti-VEGF Therapy for Cancer Business (2021–2026)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit